[BPMC] Blueprint Medicines Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 28.15 Change: 1.24 (4.61%)
Ext. hours: Change: 0 (0%)

chart BPMC

Refresh chart

Strongest Trends Summary For BPMC

BPMC is in the medium-term down -36% below S&P in 1 year. In the long-term up 216% in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-550 K Cash From Investing Activities-1.28 M Cash From Operating Activities4.89 M Gross Profit
Net Profit-11.57 M Operating Profit-11.35 M Total Assets55.91 M Total Current Assets52.18 M
Total Current Liabilities14.63 M Total Debt8.65 M Total Liabilities31.19 M Total Revenue650 K
Technical Data
High 52 week101.41 Low 52 week45.57 Last close74.49 Last change3.52%
RSI43.13 Average true range2.98 Beta1.47 Volume291.22 K
Simple moving average 20 days-0.54% Simple moving average 50 days-4.92% Simple moving average 200 days-7.44%
Performance Data
Performance Week3.09% Performance Month-8.04% Performance Quart-22.67% Performance Half-4.62%
Performance Year7.78% Performance Year-to-date38.17% Volatility daily2.18% Volatility weekly4.88%
Volatility monthly10% Volatility yearly34.64% Relative Volume181.66% Average Volume419.41 K
New High New Low

News

2020-05-29 13:13:05 | 8 Stocks Viking Global Investors Continues to Buy

2020-05-29 08:00:00 | Blueprint Medicines Announces Data Presentations at ASCO20 Highlighting Deep, Durable Clinical Activity and Well-Tolerated Safety Profile of Pralsetinib Across Broad Range of RET Fusion-Positive Tumors

2020-05-27 16:30:00 | Blueprint Medicines to Present at Upcoming Investors Conferences

2020-05-26 08:00:00 | Blueprint Medicines to Host Conference Call to Review Updated Clinical Data for Pralsetinib in RET-Altered Cancers on Friday, May 29, 2020

2020-05-18 12:16:04 | Blueprint Medicines Gets CRL for Ayvakit in Fourth-Line Gist

2020-05-15 12:10:00 | U.S. FDA declines to approve Blueprint's therapy for type of stomach cancer

2020-05-15 08:00:00 | Blueprint Medicines Receives Complete Response Letter from FDA for Avapritinib New Drug Application for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

2020-05-14 23:29:41 | Edited Transcript of BPMC earnings conference call or presentation 6-May-20 12:30pm GMT

2020-05-14 12:00:04 | All You Need to Know About Blueprint Medicines BPMC Rating Upgrade to Buy

2020-05-14 09:00:00 | Blueprint Medicines Announces Data Presentations Highlighting Significant Progress in Advancing RET-Altered Cancer and Systemic Mastocytosis Programs

2020-05-12 11:36:03 | How Blueprint Medicines BPMC Stock Stands Out in a Strong Industry

2020-05-07 12:58:04 | Blueprint Medicines BPMC Q1 Earnings Top, Revenues Soar Y/Y

2020-05-07 08:01:57 | Blueprint Medicines BPMC Q1 2020 Earnings Call Transcript

2020-05-06 08:35:12 | Blueprint Medicines BPMC Reports Q1 Loss, Tops Revenue Estimates

2020-05-06 07:00:00 | Blueprint Medicines Reports First Quarter 2020 Financial Results

2020-04-28 11:19:00 | Blueprint Medicines Tumbles 20.8% on Phase 3 Study Failure

2020-04-28 10:27:33 | P/E Ratio Insights for Blueprint Medicines

2020-04-28 07:00:00 | Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor

2020-04-16 06:30:47 | Should You Be Concerned About Blueprint Medicines Corporation's NASDAQ:BPMC Historical Volatility?

2020-04-09 12:00:04 | Blueprint Medicines BPMC Upgraded to Buy: Here's Why

2020-04-01 08:00:00 | Blueprint Medicines Announces the Achievement of Key Portfolio Milestones

2020-03-27 15:51:50 | Hedge Funds Have Never Been This Bullish On Blueprint Medicines Corporation BPMC

2020-03-16 07:00:00 | Blueprint Medicines Announces Part 1 Results from PIONEER Trial Showing Broad Activity of Avapritinib Across Measures of Mast Cell Burden, Clinical Outcomes and Quality of Life in Indolent Systemic Mastocytosis

2020-03-14 11:30:03 | Why Is Blueprint Medicines BPMC Down 21.6% Since Last Earnings Report?

2020-03-09 09:00:00 | Blueprint Medicines to Report Updated Data from the Phase 2 PIONEER Trial of Avapritinib in Indolent Systemic Mastocytosis on Monday, March 16, 2020

2020-02-19 18:16:12 | 3 “Strong Buy” Healthcare Stocks With Fast-Approaching Catalysts

2020-02-19 08:00:00 | Blueprint Medicines to Present at Upcoming Investor Conferences

2020-02-18 12:52:06 | Ipsen writes down $725M after largest-ever acquisition, trial woes

2020-02-14 10:42:03 | Blueprint Medicines BPMC Q4 Loss Narrows, Revenues Top Mark

2020-02-13 23:31:53 | Edited Transcript of BPMC earnings conference call or presentation 13-Feb-20 1:30pm GMT

2020-02-13 10:31:03 | Deciphera's NDA for GIST Drug Gets Priority Review From FDA

2020-02-13 08:25:01 | Blueprint Medicines BPMC Reports Q4 Loss, Tops Revenue Estimates

2020-02-07 11:21:04 | Blueprint Medicines' NDA for Avapritinib Gets Extended Review

2020-02-07 07:32:45 | The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns

2020-02-06 08:00:00 | Blueprint Medicines Announces PDUFA Date Extension for New Drug Application of Avapritinib for the Treatment of Adults with Fourth-Line Gastrointestinal Stromal Tumor

2020-02-03 11:27:34 | Andreas Halvorsen Trims Adaptive Biotechnologies Stake

2020-01-30 11:04:04 | Lilly's NDA for Selpercatinib Gets FDA's Priority Review

2020-01-22 22:24:00 | Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock

2020-01-22 08:25:41 | The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings

2020-01-21 16:01:00 | Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock

2020-01-16 04:59:19 | Here's Why We're Not Too Worried About Blueprint Medicines's NASDAQ:BPMC Cash Burn Situation

2020-01-13 08:00:00 | Blueprint Medicines Announces 2020 Corporate Goals

2020-01-12 12:19:00 | A Biotech Veteran Thinks He Can Undersell the Entire Drug Industry

2020-01-11 18:45:31 | How Did Blueprint Medicines Corporation BPMC Perform In Comparison to Hedge Fund Favorites in 2019?

2020-01-10 10:27:03 | Blueprint Medicines' Ayvakit Gets FDA Nod for Rare Cancer

2020-01-10 08:49:00 | Blueprint prices new cancer drug at $32,000 per month

2020-01-09 17:16:57 | FDA approves Cambridge biotech's first-ever drug for cancer

2020-01-09 15:52:00 | Blueprint Medicines Announces FDA Approval of AYVAKIT™ avapritinib for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor

2020-01-09 10:31:03 | Blueprint Medicines Posts Data From NSCLC Study on Pralsetinib

2020-01-08 08:00:00 | Blueprint Medicines Announces Top-line Data for Pralsetinib and Initiates Rolling NDA Submission to FDA for the Treatment of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer